Medicilon Appoints Dr. Christopher Stewart, DABT as Senior Scientific Advisor
저자：Medicilon 업로드：2022-04-20 조회수：
Recently, Shanghai Medicilon Inc. (stock code: 688202.SH) (Medicilon) announced the appointment of Dr. Christopher Stewart, DABT as the Senior Scientific Advisor of Medicilon. Dr. Stewart will assist the Medicilon scientific research team to better provide tailored comprehensive preclinical R&D services for international pharmaceutical R&D partners.
Dr. Christopher Stewart, DABT as Senior Scientific Advisor of Medicilon
Dr. Christopher Stewart, Postdoctoral Fellow in Toxicology, University of Arkansas School of Medicine; fellow of the American College of Toxicology and fellow of the Society of Toxicology, with over 30 years of professional experience. Dr. Stewart is currently the Principal Consultant of SGI Consulting. He has worked in research management for MPI Research, the world's largest preclinical CRO, Charles River Laboratories, Arkansas Children's Hospital, and the US FDA. He has extensive practice and deep insights into GLP regulations (including FDA, EPA, OECD and JMHLW) and ICH, and has made great achievements in the field of biomedical development. Dr. Stewart also participated in the preparation of more than 300 global application filing documents, and made positive contributions to the registration of chemical drugs and biological preparations, and the development of new drugs.
It is worth mentioning that SGI Consulting, where Dr. Stewart works, provides a wide range of non-clinical, clinical, chemical and regulatory services for global new drug R&D companies and institutions, but not limited to non-clinical project design of biopharmaceuticals and small molecules, Translational toxicology support and interpretation, regulatory training, regulatory communications, regulatory submissions, referral services, and API manufacturing and clinical support.
Dr Christopher Stewart said, "I have known and assisted Medicilon Nonclinical for many years. Now, it is my pleasure to officially join the team and provide additional support."
Dr. Chunlin Chen, Founder and CEO of Medicilon, said, "I am very excited to have Dr. Christopher Stewart to join Medicilon, As a key opinion leader in the biopharmaceutical field. Dr. Stewart has rich professional experience and extensive resources, and will provide guidance and scientific decision support for Medicilon, which will bring vital assistance to the development of Medicilon to the next stage."
Contact us:
email:marketing@medicilon.com
이전：Medecine assisted | BIOTAI bispecific neutralizing antibody drug BAT2022 was approved clinically.
다음에：Medicilon won the "Top 50 China Best Employer Award 2021"
